Pharma BD Deal Intelligence
PharmAla Biotech executes definitive license agreement granting Jupiter Neurosciences exclusive U.S. rights to ALA-002; PharmAla retains ex-U.S. rights.
Jupiter Neurosciences Form 8-K disclosing the Strategic Asset License Agreement for ALA-002 and its payment structure.
Source summaries from our enrichment pipeline; follow links for originals.
All 3 sources with sentiment breakdown →
Jupiter Neurosciences (Nasdaq: JUNS) signed a definitive Strategic Asset License Agreement with PharmAla Biotech for exclusive, perpetual, royalty-bearing U.S. rights to develop, manufacture and commercialize ALA-002, PharmAla's next-generation MDMA-class candidate, announced July 21, 2026. Total consideration is up to $100 million: a $3,333,333 upfront payment ($1.5M cash and $1,833,333 in Jupiter stock subject to a 120-day lock-up), up to $23,333,333 in development and regulatory milestones, and up to $73,333,333 in commercialization milestones tied to cumulative U.S. net-sales thresholds. PharmAla retains all rights to ALA-002 outside the U.S. The deal expands Jupiter from a single-program company into a dual clinical-stage CNS developer.
← Browse all deals · How we score deals
More: 2026 deals